Cimzia certolizumab pegol: Additional Phase III data

Additional data from the double-blind, international Phase III RAPID 1 trial showed that at 12 months, both doses of Cimzia (200 and 400 mg) plus MTX significantly improved ACR 20, 50 and 70 rates vs....